Novartis’ Cosentyx® superior to Stelara in delivering lasting skin clearance for psoriasis patients

Cosentyx launched as first-line systemic indication for psoriasis in UK in 2015 and recently approved for psoriatic arthritis and ankylosing spondylitis in Europe

Source: Pharmacy Europe - March 9, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Dermatology Patient care Research ankylosing spondylitis Cosentyx Latest News PASI psoriatic arthritis Source Type: news